Lucid Diagnostics Inc. (NASDAQ:LUCD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has earned an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $4.1250.

Several analysts recently issued reports on LUCD shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, March 26th. Ascendiant Capital Markets upped their price target on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a report on Thursday, April 9th. Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Maxim Group cut their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Wednesday, May 6th.

Institutional Trading of Lucid Diagnostics

Several institutional investors have recently added to or reduced their stakes in LUCD. Bank of America Corp DE increased its stake in Lucid Diagnostics by 41.5% during the third quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock valued at $41,000 after purchasing an additional 11,917 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in Lucid Diagnostics by 35.7% during the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after purchasing an additional 22,727 shares during the last quarter. Centiva Capital LP bought a new stake in Lucid Diagnostics during the third quarter valued at $25,000. Sprott Inc. bought a new stake in Lucid Diagnostics during the third quarter valued at $25,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Lucid Diagnostics during the first quarter valued at $39,000. 74.01% of the stock is owned by institutional investors and hedge funds.

Lucid Diagnostics Trading Down 0.8%

NASDAQ LUCD opened at $0.95 on Wednesday. The company’s fifty day simple moving average is $1.18 and its 200-day simple moving average is $1.18. Lucid Diagnostics has a 52 week low of $0.94 and a 52 week high of $1.70. The stock has a market cap of $192.31 million, a P/E ratio of -2.01 and a beta of 1.10.

Lucid Diagnostics (NASDAQ:LUCD) last posted its earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The firm had revenue of $1.26 million for the quarter, compared to analyst estimates of $1.38 million. On average, research analysts expect that Lucid Diagnostics will post -0.22 EPS for the current fiscal year.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.